Gefitinib (Iressa)

02/24/2005 - "Here we report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. "
01/01/2021 - "Gefitinib has shown good efficacy in treating recurrent or advanced non-small cell lung cancer (NSCLC), but the drug resistance remains a clinical challenge in medical oncology. "
10/01/2004 - "(8) In practice, more thorough assessment of gefitinib is needed to determine whether this new drug is beneficial for patients with non small-cell lung cancer. "
11/30/2022 - "Gefitinib is recommended as a first-line treatment option for elderly patients with non-small cell lung cancer (NSCLC). "
09/04/2020 - "Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. "

01/01/2021 - "ROC curve analysis indicated ADCpost, ΔADCpost, ΔADCpost (%), and tumor regression rate as the best predictors of efficacy of WBRT combined with gefitinib in these patients. "
08/04/2004 - "Patients with P-Akt-positive tumors who received gefitinib had a better response rate, disease control rate, and time to progression than patients with P-Akt-negative tumors, suggesting that gefitinib may be most effective in patients with basal Akt activation."
04/01/2004 - "Gefitinib dramatically reduced the proportion of viable hypoxic cells in LCC6(HER-2) and MCF-7(HER-2) tumors. "
07/01/2022 - "M2 plays an important role in efficacy and may be more effective in the treatment of metastatic tumor than gefitinib."
08/01/2013 - "The patient was immediately treated with gefitinib because the tumor was judged inoperable, but after two months she obtained an important clinical remission and was submitted to radical surgery. "

10/01/2021 - "Thus, a combination of gefitinib and SFN may be a beneficial treatment strategy for lung cancer patients with acquired resistance due to T790M mutation."
10/01/2015 - "Co-treatment with miR‑146a and gefitinib treatment showed a significant reduction of invasion in the resistant lung cancer cells induced by EMT. "
03/15/2014 - "Our data suggest additive rather than synergistic interactions between gefitinib and radiation and that a combination of short-course gefitinib and high-dose/-fraction radiation may have the greatest potential against the subsets of lung cancers harboring activating mutations in the EGFR gene."
01/01/2011 - "Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?"
04/01/2004 - "EGFR mutants render Iressa more effective in treating lung cancer."

11/01/2021 - "We present an extremely rare case of lung adenocarcinoma that was completely cured by gefitinib administration. "
02/01/2011 - "[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib]."
01/01/2007 - "[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib]."
01/01/2020 - "It was revealed that TP combined with gefitinib synergistically inhibited the migration and invasion of lung adenocarcinoma cell line A549; the combination treatment had a significantly better outcome than that of TP and gefitinib alone. "
09/01/2015 - "Gefitinib treatment significantly improved the survival of patients with advanced lung adenocarcinoma in China."

07/01/2009 - "We expected positive results from gefitinib, because the patient fitted the optimal profile: female, never smoker, adenocarcinoma histology. "
01/01/2010 - "A female Asian nonsmoker with adenocarcinoma was given gefitinib as first-line treatment with significant efficacy. "
01/01/2009 - "Gefitinib treatment was of significantly greater benefit in patients with adenocarcinoma than in those with non-adenocarcinoma (test for interaction p< 0.001). "
12/01/2008 - "Gefitinib is a molecular targeting agent and more effective in patients with characteristics of oriental ethnicity, female gender, adenocarcinoma and non-smokers. "
07/01/2013 - "In conclusion, gefitinib combined with γ-ray SBRT appears to be feasible and effective as the first-line treatment in senile patients with adenocarcinoma of the lungs."